CL2017002996A1 - Compuestos alqueno tetrasustituidos y su uso - Google Patents
Compuestos alqueno tetrasustituidos y su usoInfo
- Publication number
- CL2017002996A1 CL2017002996A1 CL2017002996A CL2017002996A CL2017002996A1 CL 2017002996 A1 CL2017002996 A1 CL 2017002996A1 CL 2017002996 A CL2017002996 A CL 2017002996A CL 2017002996 A CL2017002996 A CL 2017002996A CL 2017002996 A1 CL2017002996 A1 CL 2017002996A1
- Authority
- CL
- Chile
- Prior art keywords
- tetra
- substituted alkene
- alkene compounds
- compounds
- subject
- Prior art date
Links
- -1 alkene compounds Chemical class 0.000 title 1
- 206010006187 Breast cancer Diseases 0.000 abstract 3
- 208000026310 Breast neoplasm Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102100038595 Estrogen receptor Human genes 0.000 abstract 1
- 101710196141 Estrogen receptor Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/02—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/02—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2
- C07D317/06—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Abstract
<p>SE DESCRIBEN EN LA PRESENTE COMPUESTOS, O SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, Y MÉTODOS PARA USAR LOS COMPUESTOS PARA TRATAR CÁNCER DE MAMA POR ADMINISTRACIÓN A UN SUJETO QUE NECESITA DE LOS MISMOS UNA CANTIDAD TERAPÉUTICAMENTE EFECTIVA DE LOS COMPUESTOS O SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS. EL CÁNCER DE MAMA PUEDE SER UN CÁNCER DE MAMA ER-POSITIVO Y/O EL SUJETO QUE NECESITA DE TRATAMIENTO PUEDE EXPRESAR UNA PROTEÍNA ER-Α MUTANTE.</p>
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562168581P | 2015-05-29 | 2015-05-29 | |
| US201562168529P | 2015-05-29 | 2015-05-29 | |
| US201562269745P | 2015-12-18 | 2015-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017002996A1 true CL2017002996A1 (es) | 2018-03-23 |
Family
ID=57398096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017002996A CL2017002996A1 (es) | 2015-05-29 | 2017-11-27 | Compuestos alqueno tetrasustituidos y su uso |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US9796683B2 (es) |
| EP (2) | EP3981766A1 (es) |
| JP (1) | JP6325760B1 (es) |
| KR (1) | KR20180011274A (es) |
| CN (2) | CN113024466A (es) |
| AU (1) | AU2016271126B2 (es) |
| BR (1) | BR112017025546B1 (es) |
| CA (1) | CA2987321C (es) |
| CL (1) | CL2017002996A1 (es) |
| CO (1) | CO2017013432A2 (es) |
| CY (1) | CY1125068T1 (es) |
| DK (1) | DK3302471T3 (es) |
| ES (1) | ES2895511T3 (es) |
| HR (1) | HRP20211542T1 (es) |
| HU (1) | HUE056199T2 (es) |
| IL (1) | IL255765B2 (es) |
| JO (1) | JO3735B1 (es) |
| LT (1) | LT3302471T (es) |
| MA (1) | MA43364B1 (es) |
| MD (1) | MD3302471T2 (es) |
| MX (1) | MX2017015226A (es) |
| MY (1) | MY186977A (es) |
| PE (1) | PE20181083A1 (es) |
| PH (1) | PH12017502142A1 (es) |
| PL (1) | PL3302471T3 (es) |
| PT (1) | PT3302471T (es) |
| RS (1) | RS62481B1 (es) |
| RU (1) | RU2733741C2 (es) |
| SI (1) | SI3302471T1 (es) |
| TW (1) | TWI704137B (es) |
| UA (1) | UA120882C2 (es) |
| WO (2) | WO2016196346A1 (es) |
| ZA (1) | ZA201707912B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3302471T3 (da) | 2015-05-29 | 2021-11-15 | Eisai R&D Man Co Ltd | Tetrasubstituerede alkenforbindelser og deres anvendelse |
| US20190337921A1 (en) * | 2016-11-24 | 2019-11-07 | Eisai R&D Management Co., Ltd. | Tetrasubstituted alkene compounds and their use |
| JP2019535778A (ja) | 2016-11-24 | 2019-12-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 四置換アルケン化合物及び乳がんを治療するためのその使用 |
| RU2747399C2 (ru) * | 2016-11-28 | 2021-05-04 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Соли производного индазола и их кристаллы |
| SG11201908531WA (en) * | 2017-03-16 | 2019-10-30 | Eisai R&D Man Co Ltd | Combination therapies for the treatment of breast cancer |
| WO2019225552A1 (en) * | 2018-05-22 | 2019-11-28 | Eisai R&D Management Co., Ltd. | Salts of indazole derivative and crystals thereof |
| KR20210105384A (ko) | 2018-12-17 | 2021-08-26 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 에스트로겐 수용체 길항제 |
| CN113811333B (zh) * | 2019-05-14 | 2024-03-12 | 诺维逊生物股份有限公司 | 靶向抗癌核激素受体的化合物 |
| MX2021014349A (es) | 2019-05-24 | 2022-01-06 | Eisai R&D Man Co Ltd | Metodo para tratar cancer con una forma de dosificacion oral de un inhibidor de receptores de estrogeno-alfa. |
| MX2021015486A (es) * | 2019-06-19 | 2022-01-24 | Jiangsu Hengrui Medicine Co | Derivado de indazol, metodo de preparacion y aplicacion farmaceutica del mismo. |
| CN110452177A (zh) * | 2019-09-02 | 2019-11-15 | 南通大学 | 一种5-溴-4-氟-1h-吲唑的合成方法 |
| EP4058464A1 (en) | 2019-11-13 | 2022-09-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| JP7419575B2 (ja) | 2020-06-28 | 2024-01-22 | メッドシャイン ディスカバリー インコーポレイテッド | 縮合環インダゾール系化合物 |
| JP2023548340A (ja) * | 2020-11-06 | 2023-11-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 乳癌の治療方法 |
| CN114644615B (zh) * | 2020-12-18 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 一种吲唑类衍生物的结晶形式及其制备方法 |
| CN116615418A (zh) * | 2020-12-18 | 2023-08-18 | 江苏恒瑞医药股份有限公司 | 一种吲唑类衍生物的药学上可接受的盐、结晶形式及其制备方法 |
| CN114644616B (zh) * | 2020-12-18 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 一种吲唑类衍生物的药学上可接受的盐、结晶形式及其制备方法 |
| CN117295747A (zh) | 2021-03-23 | 2023-12-26 | 诺维逊生物股份有限公司 | 抗癌核激素受体靶向化合物 |
| CN117440950A (zh) * | 2021-06-27 | 2024-01-23 | 北京盛诺基医药科技股份有限公司 | 一种ERα受体共价结合拮抗剂 |
| CN115960082A (zh) * | 2021-10-13 | 2023-04-14 | 长春金赛药业有限责任公司 | 一种四取代的烯烃化合物、其制备方法及其在医药上的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3907290A1 (de) | 1989-03-07 | 1990-09-13 | Gerhard Prof Dr Eisenbrand | Steroidhormonrezeptoraffine antitumorwirkstoffe |
| US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| TW397821B (en) | 1996-04-19 | 2000-07-11 | American Home Produits Corp | 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof |
| US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| WO2007058626A1 (en) | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
| WO2009120999A2 (en) | 2008-03-28 | 2009-10-01 | Olema Pharmaceuticals, Inc. | Use of an endoxifen prodrug for treatment of breast cancer |
| US8063249B1 (en) * | 2008-04-25 | 2011-11-22 | Olema Pharmaceuticals, Inc. | Substituted triphenyl butenes |
| WO2011046596A2 (en) | 2009-10-13 | 2011-04-21 | Duquesne University Of The Holy Spirit, A Nonprofit Corporation Organized Under The Laws Of The Commonwealth Of Pennsylvania | Anti-cancer tamoxifen-melatonin hybrid ligand |
| WO2011129837A1 (en) | 2010-04-16 | 2011-10-20 | Olema Pharmaceuticals, Inc. | Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer |
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| WO2013056178A2 (en) | 2011-10-14 | 2013-04-18 | Foundation Medicine, Inc. | Novel estrogen receptor mutations and uses thereof |
| MX2014011217A (es) | 2012-03-20 | 2015-03-10 | Seragon Pharmaceuticals Inc | Moduladores del receptor de estrogeno y sus usos. |
| US9365510B2 (en) | 2012-04-16 | 2016-06-14 | British Columbia Cancer Agency Branch | Aziridine bisphenol ethers and related compounds and methods for their use |
| JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| WO2014205138A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulator and uses thereof |
| MX2015016171A (es) | 2013-06-19 | 2016-08-08 | Seragon Pharmaceuticals Inc | Moduladores del receptor de estrogeno de azetidina y usos de los mismos. |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| AU2015228859A1 (en) | 2014-03-13 | 2016-07-07 | F. Hoffmann-La Roche Ag | Therapeutic combinations with estrogen receptor modulators |
| WO2016055982A1 (en) | 2014-10-10 | 2016-04-14 | Acerta Pharma B.V. | Quinoline and quinazoline compounds |
| US9845291B2 (en) | 2014-12-18 | 2017-12-19 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
| DK3302471T3 (da) | 2015-05-29 | 2021-11-15 | Eisai R&D Man Co Ltd | Tetrasubstituerede alkenforbindelser og deres anvendelse |
-
2016
- 2016-05-27 DK DK16804153.1T patent/DK3302471T3/da active
- 2016-05-27 BR BR112017025546-4A patent/BR112017025546B1/pt active IP Right Grant
- 2016-05-27 CA CA2987321A patent/CA2987321C/en active Active
- 2016-05-27 CN CN202110301494.7A patent/CN113024466A/zh active Pending
- 2016-05-27 MA MA43364A patent/MA43364B1/fr unknown
- 2016-05-27 EP EP21191181.3A patent/EP3981766A1/en not_active Withdrawn
- 2016-05-27 KR KR1020177037820A patent/KR20180011274A/ko active IP Right Grant
- 2016-05-27 MX MX2017015226A patent/MX2017015226A/es unknown
- 2016-05-27 CN CN201680043755.7A patent/CN107847498B/zh active Active
- 2016-05-27 WO PCT/US2016/034782 patent/WO2016196346A1/en active Application Filing
- 2016-05-27 LT LTEPPCT/US2016/034782T patent/LT3302471T/lt unknown
- 2016-05-27 PT PT168041531T patent/PT3302471T/pt unknown
- 2016-05-27 RU RU2017146408A patent/RU2733741C2/ru active
- 2016-05-27 TW TW105116750A patent/TWI704137B/zh active
- 2016-05-27 MD MDE20180368T patent/MD3302471T2/ro unknown
- 2016-05-27 EP EP16804153.1A patent/EP3302471B1/en active Active
- 2016-05-27 ES ES16804153T patent/ES2895511T3/es active Active
- 2016-05-27 HU HUE16804153A patent/HUE056199T2/hu unknown
- 2016-05-27 US US15/167,373 patent/US9796683B2/en active Active
- 2016-05-27 RS RS20211306A patent/RS62481B1/sr unknown
- 2016-05-27 UA UAA201712962A patent/UA120882C2/uk unknown
- 2016-05-27 MY MYPI2017001740A patent/MY186977A/en unknown
- 2016-05-27 SI SI201631340T patent/SI3302471T1/sl unknown
- 2016-05-27 IL IL255765A patent/IL255765B2/en unknown
- 2016-05-27 PL PL16804153T patent/PL3302471T3/pl unknown
- 2016-05-27 WO PCT/US2016/034764 patent/WO2016196337A1/en active Application Filing
- 2016-05-27 PE PE2017002481A patent/PE20181083A1/es unknown
- 2016-05-27 HR HRP20211542TT patent/HRP20211542T1/hr unknown
- 2016-05-27 JP JP2017560920A patent/JP6325760B1/ja active Active
- 2016-05-27 AU AU2016271126A patent/AU2016271126B2/en active Active
- 2016-05-29 JO JOP/2016/0102A patent/JO3735B1/ar active
-
2017
- 2017-09-22 US US15/713,107 patent/US10851065B2/en active Active
- 2017-11-21 ZA ZA2017/07912A patent/ZA201707912B/en unknown
- 2017-11-24 PH PH12017502142A patent/PH12017502142A1/en unknown
- 2017-11-27 CL CL2017002996A patent/CL2017002996A1/es unknown
- 2017-12-27 CO CONC2017/0013432A patent/CO2017013432A2/es unknown
-
2021
- 2021-11-08 CY CY20211100961T patent/CY1125068T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017002996A1 (es) | Compuestos alqueno tetrasustituidos y su uso | |
| DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
| CL2017001943A1 (es) | Terapias de combinación para el tratamiento de cánceres | |
| CL2020001691A1 (es) | Exosomas para inmunooncología y terapia antiinflamatoria. | |
| NI201900019A (es) | Inhibidores de procesos metabólicos celulares | |
| CL2017000080A1 (es) | Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer | |
| CO2017011197A2 (es) | Terapia de combinación fgfr/pd-1 para el tratamiento del cancer | |
| DOP2016000153A (es) | Anticuerpos y fragmentos anti-vista | |
| CO2017001994A2 (es) | Compuestos activos hacia bromodominios | |
| CL2016001082A1 (es) | Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa | |
| CL2018003754A1 (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo. | |
| CR20150376A (es) | Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos | |
| NI201500062A (es) | Terapia adyuvante con inhibidores de quinasa de la familia tec | |
| CL2016002516A1 (es) | “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct | |
| AR102553A1 (es) | Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit | |
| PE20142363A1 (es) | Usos y articulo de fabricacion que incluye el inhibidor de la dimerizacion de her2 pertuzumab | |
| CL2018001722A1 (es) | Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506) | |
| CL2017000317A1 (es) | Terapia adjuntiva con 25-hidroxi vitamina d | |
| CL2017000050A1 (es) | Terapia de combinación para el cáncer | |
| CL2015003343A1 (es) | Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico. | |
| MX2018005544A (es) | Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar cancer. | |
| SV2019005822A (es) | Metodos para tratar el cáncer de próstata | |
| AR112102A1 (es) | Tinostamustina para utilizar en el tratamiento de cáncer de ovario | |
| CO2020001107A2 (es) | Moduladores terapéuticos del modo inverso de la atp sintasa | |
| MX2020004513A (es) | Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican. |